Skin irritation by dithranol cream: A blind study to assess the role of the cream formulation

Acta Dermato-Venereologica

Volumn 78, Issue 4, 1998, Pages 262-265

  Prins, M ^a   Swinkels, O Q J ^a   Kolkman, E G W ^a   Wuis, E W ^a   Hekster, Y A ^a   Van Der Valk, P G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anthralin; Erythema; Stabilizers; Vehicle

Indexed keywords

ASCORBIC ACID; DITHRANOL; SALICYLIC ACID;

ADULT; ARTICLE; AUTOOXIDATION; CATALYSIS; CLINICAL TRIAL; COLORIMETRY; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN IRRITATION; TREATMENT PLANNING;

ADMINISTRATION, TOPICAL; ADULT; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; COLORIMETRY; ERYTHEMA; FEMALE; HUMANS; MALE; OINTMENTS; PATCH TESTS; REFERENCE VALUES; SKIN; VEHICLES;

EID: 0031848346     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155598441828     Document Type: Article

References (30)

1. van de Kerkhof PCM. Dithranol treatment for psoriasis: after 75 years, still going strong! Eur J Dermatol 1991; 1: 79-88.
2. Wiegrebe W, Muller K. Treatment of psoriasis with anthrones chemical principles, biochemical aspects, and approaches to the design of novel derivatives. Skin Pharmacol 1995; 8: 1-24.
3. Ros JJW, Van der Meer YG, De Hoop D, De Kort WJ, Van Andel P. In vitro and in vivo comparison of creams containing dithranol 0.5%. Pharm Weekbl Sci 1991; 13: 210-214.
4. Melo TS, Dubertret L, Prognon P, Gond A, Mahuzier G, Santus R. Physicochemical properties and stability of anthralin in model systems and human skin. J Invest Dermatol 1983; 80: 1-6.
5. Juhlin L. Factors influencing anthralin erythema. Br J Dermatol 1981; 105: 87-91.
6. Lawrence CM, Howel D, Shuster S. The inflammatory response to anthralin. Clin Exp Dermatol 1984; 9: 336-341.
7. Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Derm Venereol Suppl (Stockh) 1979; 59: 125-132.
8. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis. Preliminary report on penetration and clinical efficacy. Br J Dermatol 1980; 102: 571-573.
9. Mustakallio KK. The history of dithranol and related hydroxyanthrones, their efficacy, side effects, and different regimens employed in the treatment of psoriasis. A review. Acta Derm Venereol Suppl (Stockh) 1992; 172: 7-9.
10. van de Kerkhof PCM, Timmerman MG. The effect of clobetasol-17-propionate and crude coal tar on dithranol-induced inflammation. A clinical and biochemical study. Acta Derm Venereol (Stockh) 1990; 70: 434-437.
11. Snater E, Janssen EA, van der Valk PG, van de Kerkhof PCM. Transepidermal water vapour loss is not increased during and following dithranol irritation. Br J Dermatol 1995; 132: 908-912.
12. Seitz JC, Whitmore CG. Measurement of erythema and tanning responses in human skin using a tri-stimulus colorimeter. Dermatologica 1988; 177: 70-75.
13. Serup J, Agner T. Colorimetric quantification of erythema-a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry. Clin Exp Dermatol 1990; 15: 267-272.
14. Fullerton A, Fischer T, Lahti A, Farber EM. Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1996; 35: 1-10.
15. Office of the British Pharmacopoeia. Dithranol Ointment; in Anonymous British Pharmacopoeia. London: HMSO, Crown Copyright 1993: 888.
16. Kneczke M, Rahm C, Landersjo L, Lundgren P. In vitro release of anthralin from white petrolatum and an o/w cream. Acta Pharm Nord 1989; 1: 249-258.
17. Kammerau B, Zesch A, Schaefer H. Absolute concentrations of dithranol and triacetyl-dithranol in the skin layers after local treatment: in vivo investigations with four different types of pharmaceutical vehicles. J Invest Dermatol 1975; 64: 145-149.
18. Schaefer H, Stuttgen G, Zesch A, Schalla W, Gazith J. Quantitative determination of percutaneous absorption of radiolabeled drugs in vitro and in vivo by human skin. Curr Probl Dermatol 1978; 7: 80-94.
19. Mustakallio KK, Kolari PJ. Irritation and staining by dithranol (anthralin) and related compounds. IV. Visual estimation of erythema compared with contact thermometry and laser Doppler flowmetry. Acta Derm Venereol (Stockh) 1983; 63: 513-518.
20. Göransson AM, Kolari PJ, Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds. V. Short-contact and tape-stripping experiments with dithranol and butantrone. Acta Derm Venereol (Stockh) 1984; 64: 134-139.
21. Timmerman MG, Mier PD, van de Kerkhof PCM. Studies on the time course of dithranol-induced inflammation by quantification of alkaline phosphatase. Acta Derm Venereol (Stockh) 1990; 70: 66-69.
22. Soschin D, Leyden JJ. Sorbic acid-induced erythema and edema. J Am Acad Dermatol 1986; 14: 234-241.
23. Kersey P, Chapman P, Rogers S, Rawlins M, Shuster S. The inflammatory response to anthralin and its relation to aryl hydrocarbon hydroxylase. Br J Dermatol 1981; 105 Suppl 20: 64-67.
24. de Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PCM. The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol 1988; 1: 259-264.
25. Kneczke M, Rahm C, Landersjo L. The influence of salicylic acid on the in vitro release of anthralin from an o/w cream. Acta Pharm Nord 1990; 2: 313-318.
26. Paramsothy Y, Lawrence CM. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin. Br J Dermatol 1987; 116: 517-519.
27. Ros JJW, Van der Meer YG. Preparation, analysis and stability of oil-in-water creams containing dithranol. Eur J Hosp Pharm 1991; 1: 77-84.
28. Green PG, Kennedy CT, Forbes DR. Anthralin stability in various vehicles. J Am Acad Dermatol 1987; 16: 984-988.
29. Muller R, Naumann E, Detmar M, Orfanos CE. Stabilität von Cignolin (Dithranol) in teerhaltigen Salben mit und ohne Salicylsäurezusatz. Oxidation in Danthron und Dithranoldimer. Hautarzt 1987; 38: 107-111.
30. Comaish S, Smith J, Seville RH. Factors affecting the clearance of psoriasis with dithranol (anthralin). Br J Dermatol 1971; 84: 282-289.